We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Fruquintinib-induced renal-limited thrombotic microangiopathy: a case report.
- Authors
Zhao, Ruiping; Fan, Ruichen; Pan, Yan; Han, Yuze; Wang, Ying; Chen, Weidong
- Abstract
Background: Fruquintinib is a highly selective inhibitor of vascular endothelial growth factor receptor (VEGFR). Currently, there are no reported cases of fruquintinib causing kidney-restrictive thrombotic microangiopathy (TMA) in the available Chinese and foreign literature. Case presentation: In this case report, we presented a 73-year-old patient receiving fruquintinib for metastatic colon cancer, manifesting abundant proteinuria, in which kidney-restrictive TMA was also diagnosed through renal biopsy. As far as we were concerned, this was the frst reported in terms of fruquintinib-induced kidney-restrictive TMA confrmed by renal biopsy. Conclusion: This case indicates that fruquintinib may result in kidney-restrictive TMA, which is a rare but life-threatening complication of cancer treatment drug. Therefore, regular monitoring of proteinuria and blood pressure is imperative for all patients undergoing anti-VEGF drug therapy. And renal biopsy should be promptly conducted to facilitate early detection of thrombotic microangiopathy.
- Subjects
VASCULAR endothelial growth factor receptors; THROMBOTIC thrombocytopenic purpura; VASCULAR endothelial growth factor antagonists; RENAL biopsy
- Publication
BMC Nephrology, 2024, Vol 25, Issue 1, p1
- ISSN
1471-2369
- Publication type
Case Study
- DOI
10.1186/s12882-024-03598-8